Argentina GMP Requirements: ISO 13485 Scope and the Two-Layer BPF Structure
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Argentina’s GMP expectation is a two-layer structure:
Layer one (the foreign manufacturer): provide a current, valid ISO 13485:2016 certificate issued by a certification body with the corresponding accreditation, and the certificate scope must cover the products under registration; or provide other equivalent GMP evidence. ANMAT retains the power to initiate a GMP inspection of the manufacturing site, and the trigger probability is higher for Class III/IV. In practice this means the certificate is not merely an annex to be filed and forgotten: its scope wording, its accreditation basis and its remaining validity all need to be checked against the specific submission before the dossier is assembled.
Layer two (the local registration holder): must obtain the Certificate of Compliance with BPF (Certificado de Cumplimiento de BPF) issued by ANMAT under Disposición 3266/2013; this certificate is valid for 5 years and is applied for under the procedures of 7425/2013 and 2096/2022. The two layers are independent obligations: a flawless ISO 13485 certificate does not discharge the local holder’s BPF duty, and the timing of the two tracks must be planned separately.
A useful way to think about the two layers is that they answer different questions. The ISO 13485 certificate answers whether the foreign manufacturer operates a quality system capable of producing the device consistently, while the BPF compliance certificate answers whether the local establishment is qualified to import and hold the product on the Argentine market. The two questions are asked of different entities, under different instruments, on different cycles, and neither answer substitutes for the other in the file.
2. Legal basis
| Regulatory instrument | Number | Publication date | Relevant provisions |
|---|---|---|---|
| Good Manufacturing Practices (BPF/GMP) | Disposición ANMAT 3266/2013 | 2013 | Provisions on GMP requirements; provisions on the BPF compliance certificate |
| Establishment licensing procedures | Disposición ANMAT 7425/2013; 2096/2022 | 2013 / 2022 | Provisions on the BPF certificate application procedure |
| MERCOSUR technical regulation for medical device registration | GMC/RES 25/21 | October 13, 2021 | Part III (technical documentation requirements) |
| Simplified licensing pathway for low-risk establishments | Disposición ANMAT 8799/2025 | Published November 28, 2025, effective 60 administrative working days after publication | Provision retaining GMP obligations |
For project planning purposes, the table also shows why GMP evidence sits on the critical path rather than alongside it. The BPF certificate runs on a procedure distinct from the product registration and has a 5-year validity of its own, so its renewal can fall due in the middle of a product lifecycle event such as a change or a renewal, and the two procedures then have to be coordinated rather than run independently. Mapping both cycles on the same calendar is the simplest way to avoid that collision.
3. Expert insights
Insight 1: a scope mismatch is a more common ground for rejection than an expired certificate. If the scope description of the ISO 13485 certificate does not match the products under registration, for example a certificate covering single-use infusion devices while the submitted product is an active monitoring device, ANMAT will require clarification or a fresh submission. As a rule of thumb, the scope description should be broader than, never narrower than, the submitted product, and the wording should be compared line by line with the product description in the dossier.
Insight 2: 8799/2025 simplified establishment licensing, but it did not simplify GMP. Companies using the affidavit pathway must still comply with 3266/2013, retain evidence of compliance and accept periodic inspections. The provision makes clear that procedural simplification shifts responsibility forward rather than lowering requirements. Reading the reform as a relaxation of quality obligations is precisely the misunderstanding the provision was written to close off.
Insight 3: MDSAP and ISO 13485 can serve as equivalent evidence in practice. Against the background of the practical difficulty of inspecting sites abroad, ANMAT, in addition to verifying foreign plant GMP or updated certificates, accepts certificates of conformity with the current ISO 13485 standard or MDSAP certificates issued by competent authorities as evidence of plant requirements. Companies holding MDSAP can submit it as supplementary material, which is particularly useful when the ISO 13485 scope wording leaves room for interpretation.
4. Practical recommendations
- Check the scope wording before applying. Confirm that the scope description covers the category and the processes of the submitted product, and where necessary ask the certification body for a scope clarification letter to be attached to the dossier.
- Set up an expiry alert for the certificate. Start the reassessment cycle about 6 months before ISO 13485 certificate expiry, so the renewed certificate is in hand before the review window opens rather than catching up mid-review.
- Schedule layer-two GMP separately. The local holder’s BPF compliance certificate must be applied for under the procedures of 7425/2013 and 2096/2022 and cannot be estimated together with the product registration timeline; give it its own owner and milestone.
- Run a mock inspection for Class III/IV in advance. Focus the remediation on six areas: facility and equipment maintenance, production process control, cleaning and disinfection, material traceability, training records, and adverse event and recall procedures.
5. Verification checklist
- □ ISO 13485:2016 certificate current and the certification body duly accredited
- □ Certificate scope description covers the submitted product
- □ Feasibility of adding an MDSAP certificate as equivalent evidence assessed
- □ Local holder’s BPF compliance certificate (3266/2013) obtained and within validity
- □ Expiry alert mechanism established for the ISO 13485 certificate
- □ Mock GMP inspection of the manufacturing site completed for Class III/IV
Regulatory information verified as of October 29, 2026.
In Argentina, GRZAN operates a wholly owned subsidiary that can serve as the registration holder and importer of record for foreign manufacturers, directly handling classification assessment, pathway selection, building the GMP and CFS documentation chain, Spanish-language localization of technical documentation and labeling, HELENA submissions and responses to deficiency letters, as well as BONITA import notifications, operation of the ARGOS vigilance system, change maintenance and planning for the 5-year renewal. For support with registration dossiers and conformity documentation for the Argentine market, contact the GRZAN regulatory team at info@grzanglobal.com.
The GRZAN regulatory team consists of professionals with many years of hands-on experience in international registrations, tracks the activity of regulatory authorities across markets on an ongoing basis, and applies a writing standard of conclusions first, traceable sources and verifiable figures to everything it publishes. For a market access plan tailored to a specific product in Argentina or the wider MERCOSUR region, the GRZAN regulatory team welcomes your enquiry at info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us